BRIEF published on 07/24/2026 at 12:17, 3 months 22 days ago Invus Public Equities réduit sa participation dans MAAT PHARMA Droits De Vote Franchissement De Seuil Cession D'actions MaaT Pharma Invus
PRESS RELEASE published on 07/24/2026 at 12:12, 3 months 22 days ago Franchissement de seuils Déclaration de franchissement de seuils par Invus Public Equities, L.P. pour MAAT PHARMA sur Euronext Paris Euronext Paris Déclaration Franchissement De Seuils MaaT Pharma Invus Public Equities
BRIEF published on 07/02/2026 at 18:35, 4 months 12 days ago Current status of MaaT Pharma shares and voting rights Euronext Paris Voting Rights Biotechnology Actions MaaT Pharma
BRIEF published on 07/02/2026 at 18:35, 4 months 12 days ago Situation actuelle des actions et droits de vote de MaaT Pharma Euronext Paris Droits De Vote Biotechnologie Actions MaaT Pharma
PRESS RELEASE published on 07/02/2026 at 18:30, 4 months 12 days ago Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital MaaT Pharma publie le nombre total d'actions et de droits de vote au 30 juin 2026 conformément à l'article 223-16 du Règlement Général de l'AMF Droits De Vote Capital Social AMF MaaT Pharma Biotechnologies
BRIEF published on 06/30/2026 at 13:13, 4 months 14 days ago La demande d'autorisation de mise sur le marché du MaaT013 de MaaT Pharma subit un revers. Maladie Du Greffon Contre L'hôte MaaT Pharma Décision Du CHMP Application Marketing Appel En Réexamen
BRIEF published on 06/30/2026 at 13:13, 4 months 14 days ago MaaT Pharma's Marketing Application for MaaT013 Faces Setback Graft-versus-Host Disease MaaT Pharma CHMP Decision Marketing Application Re-examination Appeal
PRESS RELEASE published on 06/30/2026 at 13:08, 4 months 14 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review First Berlin Equity Research updates rating and price target for MaaT Pharma SACA after CHMP's negative opinion on MAA for MaaT013 in aGvHD First Berlin Equity Research CHMP AGvHD MaaT Pharma SACA MAA
BRIEF published on 06/26/2026 at 07:35, 4 months 19 days ago MaaT Pharma va contester le verdict négatif du CHMP concernant MaaT013 Thérapies Écosystémiques Du Microbiome MaaT Pharma Maladie Aiguë Du Greffon Contre L'hôte MaaT013 Xervyteg Réexamen CHMP
BRIEF published on 06/26/2026 at 07:35, 4 months 19 days ago MaaT Pharma to Challenge Negative CHMP Verdict for MaaT013 Microbiome Ecosystem Therapies MaaT Pharma Acute Graft-versus-Host Disease CHMP Re-examination MaaT013 Xervyteg
Published on 11/14/2026 at 12:56, 23 hours 25 minutes ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 1 day 10 hours ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 1 day 11 hours ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 1 day 11 hours ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 1 day 12 hours ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 1 day 12 hours ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 1 day 14 hours ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 1 day 17 hours ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 1 day 17 hours ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 11:35, 2 days ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 2 days ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 2 days 4 hours ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 2 days 13 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
